Stocks to Watch: Rumble, Lexicon Pharmaceuticals

WSJDec 21 07:19

FDA Rejects Lexicon's Zynquista for Diabetes, Kidney Disease

Seeking AlphaDec 21 06:30

Lexicon Fails to Secure FDA Approval for Zynquista -- Shares Fall After Hours

MT NewswiresDec 21 05:53

Lexicon Receives Complete Response Letter for Zynquista; Says This Expected Communication From The FDA Aligns With Previously Disclosed Strategic Decision To Discontinue Launch Preparations For Zynquista And Focus Solely On Its Clinical Development...

BenzingaDec 21 05:34

Express News | Lexicon Pharmaceuticals Inc - to Discontinue Zynquista Launch Preparations

BreakingsDec 21 05:31

Express News | Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (Sotagliflozin)

BreakingsDec 21 05:30